J&J Q3 Earnings: How Oncology Surge & Strategic Spin-Off Fuel Growth
J&J’s Q3 Triumph Defies Major Patent Cliff
Investors eyeing healthcare blue chips faced a puzzle: Johnson & Johnson posted robust Q3 results yet saw its stock dip. After analyzing their earnings call and strategy shifts, I believe this reaction overlooks exceptional operational execution against severe headwinds. J&J delivered $24 billion in Q3 sales (5.4% operational growth) and an adjusted EPS beat at $2.80 vs. $2.76 forecasts. But the real story lies in how they absorbed a 42% collapse in Stelara revenue—their second-best selling drug—while still growing. This analysis reveals why their strategic pivot positions them for accelerated growth through 2026.
Unpacking the Stelara Offset: Oncology Emerges as Powerhouse
Stelara’s biosimilar competition created a staggering 10.7-percentage-point drag on Innovative Medicine growth. Yet the segment grew 5.3% operationally. How? A 20% surge in oncology sales filled the gap. Key drivers include:
- Darzalex (Multiple Myeloma): 20% growth, maintaining dominance
- Carvykti (CAR-T Therapy): >80% jump, validating cell therapy bets
- Rylaze/Luzu (Lung Cancer Combo): >100% operational growth
The video cites these as evidence of J&J’s shift from "volume to value" therapies. In my assessment, this isn’t just recovery—it’s a fundamental portfolio transformation. Immunology also contributed heavily, with Tremfya (psoriasis/IBD) up 40.1%, directly replacing Stelara’s erosion.
MedTech’s Strategic Reshaping: The Ortho Spin-Off Rationale
MedTech grew 5.6%, fueled by strategic acquisitions:
- Abiomed (Heart Pumps): >15% growth
- Shockwave (IVL Tech): ~21% surge
- Electrophysiology: ~10% expansion
Orthopedics—historically slower-growth—returned to growth (2.4%). But J&J announced a tax-free spin-off of this unit within 18-24 months. Why spin off a recovering business? The video explains it sharpens focus on higher-growth cardiovascular and advanced surgery. I’ve observed this mirrors sector trends: companies like GE HealthCare achieved multiple expansion by shedding lower-margin units. J&J expects this move to:
- Boost MedTech’s growth rate immediately
- Improve operating margins by ≥75 basis points
- Free capital for targeted M&A in priority areas
Forward Guidance: Why 2026 Growth Could Exceed Expectations
Despite raising 2025 sales guidance to $93.7B (5.7% growth), J&J held EPS guidance flat due to higher taxes from the U.S. BEAT Act. Their 2026 projection is more revealing:
- Revenue growth exceeding 5%—above current 4.6% consensus
- Driven by newer launches: Tremfya (IBD), RYBREVANT (lung cancer), and novel therapies
- InLeyto drug-delivery system: Potential $5B peak sales in bladder cancer
- Oral Psoriasis Drug (Icotekin): Submissions underway, replacing injections
The CEO emphasized "no need for large M&A" to hit targets. While seemingly contradictory after Abiomed/Shockwave, the video clarifies their strategy: "targeted deals" augmenting a $15B R&D pipeline. From my perspective, this disciplined capital allocation—spinning off Ortho while investing in cardiovascular and oncology—creates a leaner growth machine.
Innovation Pipeline Validating Strategic Focus
J&J showcased three developments confirming their R&D bets:
- InLeyto Approval: First drug-releasing system for bladder cancer (FDA-approved)
- Tremfya Subcutaneous Dosing: Only IL-23 inhibitor with full under-the-skin regimen for IBD
- Impella CP Heart Pump Data: 16.3% mortality reduction in cardiogenic shock (600-day life extension)
The Impella data, derived from the Abiomed acquisition, exemplifies how targeted M&A delivers measurable patient impact. As the video notes, this is "high-value innovation"—not just revenue growth.
Key Takeaways & Actionable Investor Analysis
- Core Portfolio Strength: J&J proved it can overcome massive patent cliffs via oncology/immunology innovation—not just cost-cutting.
- Strategic Agility: The Ortho spin-off isn’t retreat; it’s proactive portfolio optimization for higher margins and growth.
- 2026 Confidence: Pipeline productivity justifies above-consensus guidance.
Critical Investor Question: Does shedding Ortho truly free enough capital and management focus to sustain their innovation velocity? Post-spinoff execution will be decisive.
Recommended Resources
- SEC Filings (10-Q): Verify segment performance and tax guidance (source: SEC EDGAR)
- Evaluate Pharma: Track prescription trends for Carvykti/RYBREVANT (authoritative market data)
- American Heart Association Journals: Assess Impella real-world adoption post-Danger Shock trial
"J&J didn’t just survive the Stelara cliff—they used it to accelerate their pivot to higher-value therapeutics."
— Analysis based on earnings call trends
Your Move: Which strategic shift—oncology focus or MedTech spin-off—do you view as most impactful for long-term shareholders? Share your perspective below.
